Trial Profile
An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Anti-SARS-CoV-2 hyperimmune globulin therapy-Grifols (Primary) ; COVID-2019 immune globulins (Human) (Primary) ; CoVIg-19 (Primary) ; Immune globulin (Primary) ; Remdesivir
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Acronyms INSIGHT 13; ITAC
- 09 Aug 2021 Status changed from active, no longer recruiting to completed.
- 02 Apr 2021 Topline results published in the Grifols Media Release
- 02 Apr 2021 Primary endpoint of Ordinal Outcome Scale - Day 7 has not been met, according to a Takeda media release.